Impact of Obesity on Gynecological Diseases

2017 ◽  
pp. 65-76
Author(s):  
Laurice Bou Nemer
2016 ◽  
pp. 72-74 ◽  
Author(s):  
M. Makarenko ◽  
◽  
D. Govsieiev ◽  
O. Gromova ◽  
L. Martynova ◽  
...  

The objective: to study the incidence of gynecological diseases, clinical and hormonal parameters of the menstrual cycle in patients with benign hyper-plastic processes of breasts. Patients and methods. 65 women with various forms of mastitis were investigated. The following investigations were conducted: mammologistic and gynecological investigation, mommologistic X-ray investigation, ultrasound of breasts and of the pelvic organs, endometrial aspiration biopsy that was followed by cytology; when it was necessary the diagnostic laparoscopy, colposcopy, hysteroscope with curettage and morphological investigation of the endometrium, hormone research and rectal temperature measurements were conducted. Results. The frequency of the benign breast diseases was set: fibrocystic disease of breast – 32 women (49.2±6.20%), fibrous of breast – 16 women (24.6±5.34%), nodular of breasts – 8 women (12.3±4.07%), fibroadenoma – 6 women (9.2±3.59%), nodular disease of breasts on the background of fibroid changes – 3 women (4.6±2.60%). All in all, 96.9±2.14% of the patients had any gynecological diseases. Thus, the average age of the ‘debut’ of mastitis was 31.4±1.09 years; the hyper-plastic processes in the uterus was 35.2±1.17 years. Anovulation was detected in 17 (47.2±8.3%) patients, the lack of the luteal phase (NLF) was detected in 11 (30.6±7.6) patients. Conclusions. Identified hormonal changes are typical for patients with the hyper-plastic processes of the reproductive organs with different localization (breasts, uterus, ovaries). Due to the commonality of the hormone changes in most cases mastitis is combined with the various gynecological diseases (96.9±2.14%). Key words: gynecological pathology, hormonal changes, breast, factors of risk.


Maturitas ◽  
2021 ◽  
Author(s):  
Anne-Laure Madika ◽  
Conor James MacDonald ◽  
Amandine Gelot ◽  
Sixtine Hitier ◽  
Claire Mounier-Vehier ◽  
...  

2020 ◽  
Vol 9 (5) ◽  
pp. 1460
Author(s):  
Stoyan Kostov ◽  
Stanislav Slavchev ◽  
Deyan Dzhenkov ◽  
Dimitar Mitev ◽  
Angel Yordanov

The term “spaces” refers to the areas delimited by at least two independent fasciae and filled with areolar connective tissue. However, there is discrepancy regarding the spaces and their limits between clinical anatomy and gynecologic surgery, as not every avascular space described in literature is delimited by at least two fasciae. Moreover, new spaces and surgical planes have been developed after the adoption of laparoscopy and nerve-sparing gynecological procedures. Avascular spaces are useful anatomical landmarks in retroperitoneal anatomic and pelvic surgery for both malignant and benign conditions. A noteworthy fact is that for various gynecological diseases, there are different approaches to the avascular spaces of the female pelvis. This is a significant difference, which is best demonstrated by dissection of these spaces for gynecological, urogynecological, and oncogynecological operations. Thorough knowledge regarding pelvic anatomy of these spaces is vital to minimize morbidity and mortality. In this article, we defined nine avascular female pelvic spaces—their boundaries, different approaches, attention during dissection, and applications in obstetrics and gynecology. We described the fourth space and separate the paravesical and pararectal space, as nerve-sparing gynecological procedures request a precise understanding of retroperitoneal spaces.


GYNECOLOGY ◽  
2020 ◽  
Vol 22 (6) ◽  
pp. 101-107
Author(s):  
Vera N. Prilepskaya ◽  
Lana L. Bostandzhian

Since the first pill, there has been a significant evolution of hormonal contraception: low- and micro-dose drugs have appeared, drugs with components as close as possible to endogenous hormones have been developed, new dosage regimens and routes of contraceptive administration have been created. Modern combined oral contraceptives are not only used to prevent unwanted pregnancies, but are also widely used to treat a number of gynecological and non-gynecological diseases. In recent years, two new combined oral contraceptives with folate supplementation have been developed. The main purpose of adding folate to contraceptives is the prevention of fetal malformations, which is ensured by an increase in the level of folate in the body of women of reproductive age against the background of contraception and after its withdrawal.


1937 ◽  
Vol 33 (2) ◽  
pp. 152-155
Author(s):  
N. N. Kovyazin ◽  
S. A. Kopyrin

Recently, we have a number of reports on the use of ammoniacal compounds of silver in the clinic of surgical and gynecological diseases in various inflammatory, purulent and septic processes. The authors of these reports ascribe a strong antiseptic, bactericidal effect to ammonia solutions of silver in comparison with other drugs.


1927 ◽  
Vol 23 (8) ◽  
pp. 851-851

In order to prevent gynecologic diseases due to postpartum disorders, Miller points out the main points in maternity care. Every woman in labor should be examined at least two months after delivery.


2017 ◽  
pp. 10-15
Author(s):  
L.G. Nazarenko ◽  
◽  
N.S. Nestertsova ◽  

The relationship between the body weight of women at birth and the development in the future of gynecological diseases or deviations in the development of the reproductive system, development of oncological diseases and the timing of menopause have been analyzed. The results of clinical studies conducted at different times in different countries of the world, which cover the topic of this article, are presented. An overview of the world literature presented in the article, substantiates the relevance of conducting relevant research in the Ukrainian population. Key words: low birth weight, large-for-gestational-age fetus, gynecology disease.


Author(s):  
Bharti Choudhary Parihar ◽  
Priyanka Tiwari

ABSTRACTBackground: Menopause is a natural step in ageing process represents the period end of menstruation after last menstrual period in previous 12 months. Gynaecological disorder in older women differs from those who are younger. Disorders peculiar to ageing are pelvic organ prolapse, urinary incontinence, genital infections and malignancies. Present study is contemplated with a view to assess the magnitude of postmenopausal gynaecological morbidity. The goal of this study was to assess the age of onset of menopause and the spectrum of different gynaecological diseases, their incidence, diagnosis and treatment modality in postmenopausal females.Methods: A Prospective observational study of postmenopausal females attending Gynecology OPD or admitted in Sultania Zanana Hospital, Bhopal was carried out between July 2014 to June 2015. Total 401 postmenopausal females were included. Age of menopause and detail of all gynecological problems were recorded using predesigned proforma.Results: The study population was drawn from both rural (41.4%) and urban (58.8%) areas. Mean age of onset of menopause was 48.01 years in study population. In all, 28.4% had pelvic organ prolapse, 26.6% had genital malignancies, 25.5% had urogenital infections and 17.7% had benign disorder like senile endometritis, fibroid uterus etc.Conclusions: Menopausal health has been one of the neglected area in our country and needs timely vital attention as they are at risk of developing various genital malignancies. This emphasises the need for a screening programme for Indian women in our scenario.


1998 ◽  
Vol 44 (12) ◽  
pp. 2530-2536 ◽  
Author(s):  
Huub E van Ingen ◽  
Daniel W Chan ◽  
Walter Hubl ◽  
Hayato Miyachi ◽  
Rafael Molina ◽  
...  

Abstract The CA 125 II assay on the Elecsys® 2010 analyzer was evaluated in an international multicenter trial. Imprecision studies yielded within-run CVs of 0.8–3.3% and between-day CVs of 2.4–10.9%; CVs for total imprecision in the manufacturer’s laboratory were 2.4–7.8%. The linear range of the assay extended to at least 4500 kilounits/L (three decades). Interference from triglycerides (10.3 mmol/L), bilirubin (850 μmol/L), hemoglobin (1.1 mmol/L), anticoagulants (plasma), and several widely used drugs was undetectable. Method comparisons with five other CA 125 II assays showed good correlation but differences in standardization. A 95th percentile cutoff value of 35 kilounits/L was calculated from values measured in 593 apparently healthy (pre- and postmenopausal) women. In 95% of patients with benign gynecological diseases CA 125 was ≤190 kilounits/L; 63% of patients with newly diagnosed ovarian carcinoma had values >190 kilounits/L. A comparison of CA 125 values obtained with the Elecsys test and with other common CA 125 tests in monitored patients being treated for ovarian cancer showed identical patterns. In conclusion, the Elecsys CA 125 II assay is linear over a broad range, yields precise and accurate results, is free from interferences, and compares well with other assays.


Sign in / Sign up

Export Citation Format

Share Document